Recurrence-Free Survival

Recurrence-free survival (RFS) is the length of time after primary treatment (usually surgery, sometimes combined with chemotherapy or radiation) during which a patient remains alive with no detectable return of cancer. It is a key measurement used to judge how well a treatment has controlled the disease. RFS is reported in months or years and is often shown as a curve showing the percentage of patients still recurrence-free at various time points.

Origin

The concept emerged in mid-20th century oncology clinical trials as researchers sought outcome measures beyond overall survival to evaluate cancer treatments. The term became standardized in surgical oncology literature in the 1970s and 1980s and is now a core endpoint in mesothelioma surgical studies, including trials of extrapleural pneumonectomy and pleurectomy/decortication.

Significance in Asbestos Context

For patients with pleural or peritoneal mesothelioma who undergo aggressive treatment such as cytoreductive surgery, RFS is one of the main numbers oncologists use to discuss how a treatment is working and what to expect. Because mesothelioma frequently recurs even after successful surgery, RFS tends to be shorter than in many other cancers, and the timing of recurrence often shapes decisions about second-line chemotherapy, immunotherapy, or clinical trial enrollment. In legal claims, RFS data from medical records (including imaging reports, surgical pathology, and follow-up notes) can help document the course of the disease, the burden of repeated treatment, and the prognosis used in calculating damages for pain, suffering, and loss of life expectancy.

Example Sentence

After her cytoreductive surgery and HIPEC for peritoneal mesothelioma, her oncologist explained that the median recurrence-free survival in published series is roughly two years, and they would monitor with CT scans every three months.

Related Terms

Overall Survival, Progression-Free Survival, Cytoreductive Surgery, Extrapleural Pneumonectomy, Pleurectomy/Decortication, Prognosis

Notes

• Ask your oncologist to distinguish between recurrence-free survival, progression-free survival, and overall survival when discussing treatment outcomes. They are not interchangeable and mean different things for planning.
• Request copies of every surveillance imaging report (CT, PET, MRI) and the radiologist's comparison to prior scans; these documents establish the date recurrence was first detected and are important for both medical and legal records.
• If recurrence is found, ask whether tissue can be re-biopsied for molecular testing, as this may open eligibility for clinical trials or targeted therapies.
• Keep a personal timeline of surgery dates, treatment cycles, scan dates, and symptom changes. This becomes valuable for second opinions and for documenting damages in a legal claim.